An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA

Clinical Toxicology

Volumn 53, Issue 10, 2015, Pages 950-956

  Tyndall, Joseph A ^a   Gerona, Roy ^b   De Portu, Giuliano ^a   Trecki, Jordan ^c   Elie, Marie Carmelle ^a   Lucas, Judith ^a   Slish, John ^a   Rand, Kenneth ^a   Bazydlo, Lindsay ^a,d   Holder, Martina ^e   Ryan, Matthew F ^a   Myers, Paul ^f   Iovine, Nicole ^a   Plourde, Michelle ^e   Weeks, Emily ^a   Hanley, James R ^g   Endres, Greg ^h   St Germaine, Danielle ^h   Dobrowolski, Paul J ^h   Schwartz, Michael ⁱ  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Drug Enforcement Administration   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

^f FLORIDA DEPARTMENT OF HEALTH   (United States)

^g OCHSNER MEDICAL CENTER   (United States)

^h Cayman Chemical   (United States)

ⁱ NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

CNS psychological; Metabolic; Organ tissue specific; Respiratory support; Synthetic cannabinoids

Indexed keywords

CANNABINOID; DESIGNER DRUG; INDAZOLE DERIVATIVE; N-(1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE; VALINE;

ADOLESCENT; ADULT; ARTICLE; ASSISTED VENTILATION; CHEMICAL INDUSTRY; CLINICAL ARTICLE; DELIRIUM; DRUG EXPOSURE; EPIDEMIC; FEMALE; HALLUCINATION; HUMAN; INTENSIVE CARE; LAW ENFORCEMENT; MALE; MORBIDITY; OBSERVATIONAL STUDY; PUBLIC HEALTH; SEIZURE; ACUTE DISEASE; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; BIOTRANSFORMATION; CANNABINOIDS; DELIRIUM; DESIGNER DRUGS; DISEASE OUTBREAKS; FEMALE; HUMANS; INDAZOLES; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; RETROSPECTIVE STUDIES; VALINE; YOUNG ADULT;

EID: 84949099672     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1100306     Document Type: Article

References (23)

1. Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 2015; 373: 103-107
2. Centers for Disease Control and Prevention. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use -United States, January-May 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 618-619
3. Centers for Disease Control and Prevention. Notes from the field: severe illness associated with reported use of synthetic marijuana -Colorado, August-September 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 1016-1017
4. Lapoint J, James, LP, Moran CL. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011; 49: 760-764
5. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. 76 FR 11075; 2011
6. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. 78 FR 28735; 2013
7. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I. 79 FR 7577; 2014
8. Schedules for controlled substances: temporary placement of three synthetic cannabinoids into schedule I. 80 FR 5042; 2015
9. Synthetic Drug Abuse Prevention Act (SDAPA). x 1152 of Food and Drug Administration Safety and Innovation Act. (FDASIA), Pub. L. 112-144. July 9, 2012
10. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012; 50: 733-742
11. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 2013; 31: 93-100
12. Erratico C, Negreira N, Norouzizadeh H, Covaci A, Neels H, Maudens K, van Nuijs AL. In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA. Drug Test Anal 2015; 10: 866-876
13. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008; 20: 10-14
14. Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 2014; 26: 53-78
15. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180
16. Pourmand A, Armstrong P, Mazer-Amirshahi M, Shokoohi H. The evolving high: new designer drugs of abuse. Hum Exp Toxicol 2014; 33: 993-999
17. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin N Am 2014; 32: 1-28
18. Musselman ME, Hampton JP. Not for human consumption: a review of emerging designer drugs. Pharmacotherapy 2014; 34: 745-757
19. U.S. Drug Enforcement Administration. (DEA). National forensic laboratory information system: year 2013 annual report. Springfield, VA: U.S. Drug Enforcement Administration; 2014
20. American Association of Poison Control Centers. Synthetic Marijuana; 2014. www.aapcc.org. (Accessed 15 October 2015
21. Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use -multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 93-98
22. U.S Drug Enforcement Administration (DEA). Background information and evaluation of 'three factor analysis' (factors 4, 5, and 6) for temporary scheduling: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ABCHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201). 2014
23. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I.80 FR 5042; 2015